Rilvegostomig Alpha is named as an intervention in 14 current clinical trials in our China register. 8 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Jiangsu HengRui Medicine Co., Ltd (2). The most-studied condition is Gastroesophageal Junction Adenocarcinoma.
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
| Study | Phase | Status | Lead sponsor | Registers |
|---|
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
| Condition (as registered) | Trials |
|---|---|
| Gastroesophageal Junction Adenocarcinoma | 3 |
| Gastric Cancer (GC) | 2 |
| Pancreas Ductal Adenocarcinoma | 1 |
| Advanced Gastric Cancer | 1 |
| Metastatic Gastric Cancer | 1 |
| Hepatocellular Carcinoma(HCC) | 1 |
| Locally Advanced or Metastatic Non-small Cell Lung Cancer | 1 |
| Gastric Adenocarcinoma | 1 |
| Siewert Type II Adenocarcinoma of the Esophagogastric Junction | 1 |
| ESCC | 1 |
| Advanced Intrahepatic Cholangiocarcinoma | 1 |
| Locally Advanced Pancreatic Cancer | 1 |
| Metastatic Pancreatic Cancer | 1 |
| Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma | 1 |
| Colorectal Cancer Metastatic | 1 |
| Intrahepatic Cholangiocarcinoma (Icc) | 1 |
| Neoadjuvant Therapy | 1 |
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 14 | 8 |
A trial with sites in more than one country appears in each of those registers.
14 current trials in our China register name Rilvegostomig Alpha (also registered as SHR-1701) as a drug or biological intervention, as of the registry sync on 5 October 2026. Completed and withdrawn studies are not counted.
Yes. 8 of the 14 trials are recruiting: 8 with sites in China. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Jiangsu HengRui Medicine Co., Ltd (2), The First Affiliated Hospital with Nanjing Medical University (2), Fudan University (2) and Jingdong Zhang (1), among 11 lead sponsors in total. The number in brackets is how many trials each organisation leads.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Rilvegostomig Alpha works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Rilvegostomig Alpha works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Rilvegostomig Alpha (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 5 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
